Mallinckrodt‘s patent outlines methods for identifying premature infants at risk for bronchopulmonary dysplasia (BPD) and those likely to benefit from inhaled nitric oxide therapy. It includes a claim for a method involving genetic analysis to determine therapeutic response potential to inhaled nitric oxide in infants under 30 weeks gestation. GlobalData’s report on Mallinckrodt gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Mallinckrodt, was a key innovation area identified from patents. Mallinckrodt‘s grant share as of June 2024 was 57%. Grant share is based on the ratio of number of grants to total number of patents.
The patent US12007399B2 outlines a method for identifying premature infants who are likely to benefit from inhaled nitric oxide therapy, particularly in reducing the risk of bronchopulmonary dysplasia (BPD). The method involves obtaining a blood or tissue sample from infants under 30 weeks gestational age and analyzing it for specific genetic mutations in the nitric oxide synthase gene. The presence of these mutations, particularly T-786C or G894T in the endothelial nitric oxide synthase (eNOS) gene, indicates a decreased endogenous synthesis of nitric oxide, suggesting that the infant may respond positively to inhaled nitric oxide treatment. The analysis can be performed using techniques such as single nucleotide polymorphism analysis or restriction fragment length polymorphism analysis.
Additionally, the patent describes a method to mitigate risks associated with administering inhaled nitric oxide to at-risk premature infants. This involves testing for plasma concentrations of nitrate and nitrite, measuring nitric oxide levels in exhaled air, and checking for the aforementioned genetic mutations. If the plasma nitrate and nitrite levels are above 50 µM, or if nitric oxide levels in exhaled air are 2.5 ppb or higher, or if no genetic mutation is present, the infant may be treated with non-inhaled nitric oxide modalities. Conversely, if the nitrate and nitrite levels are below 50 µM, nitric oxide levels are less than 1.5 ppb, or if the genetic mutation is present, inhaled nitric oxide therapy may be administered to reduce the likelihood of developing BPD.
To know more about GlobalData’s detailed insights on Mallinckrodt, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
